{"prompt": "['>ULN and <5.0xULN,', 'investigator assessment, then treat as', 'whether normal or', 'Grade 2 event.', 'elevated at baseline)', 'For all grades, see instructions at bottom', 'of shaded area if transaminase rise is not', 'isolated but (at any time) occurs in setting', 'of either increasing bilirubin or signs of', 'DILI/liver decompensation', 'Grade 2', 'Hold study drug/study regimen dose', 'For Grade 2:', 'until Grade 2 resolution to Grade 1', '-', '(Isolated AST or ALT', 'Regular and frequent checking of LFTs (e.g., every 1 to 3 days) until', '>5.0xULN and', 'or baseline.', 'elevations of these are improving or resolved.', '-', 'If toxicity worsens, then treat as', 'Recommend consult hepatologist; consider abdominal ultrasound,', '8.0xULN, if normal at', 'Grade 3 or Grade 4.', 'including Doppler assessment of liver perfusion.', 'baseline)', '-', 'Consider, as necessary, discussing with study physician.', 'If toxicity improves to Grade 1 or', '-', 'If event is persistent (>3 to 5 days) or worsens, and investigator', 'baseline, resume study drug/study', 'suspects toxicity to be immune-mediated AE, recommend to start', '(Isolated AST or ALT', 'regimen after completion of steroid taper.', 'prednisone 1 to 2 mg/kg/day PO or IV equivalent.', '>2.0xbaseline and', '-', 'If still no improvement within 3 to 5 days despite 1 to 2 mg/kg/day of', '<12.5xULN, if elevated', 'prednisone PO or IV equivalent, consider additional workup and', 'treatment with IV methylprednisolone 2 to 4 mg/kg/day.', '>ULN at baseline)', 'If still no improvement within 3 to 5 days despite 2 to 4 mg/kg/day of', 'IV methylprednisolone, consider additional abdominal workup', '(including liver biopsy) and imaging (i.e., liver ultrasound), and', 'consider starting immunosuppressives (i.e., mycophenolate mofetil).', 'Discuss with study physician if mycophenolate mofetil is not available.', 'Infliximab should NOT be used.', 'Grade 3', 'Hold study drug/study regimen dose', 'For Grade 3:', 'until resolution to Grade 1 or', '-', '(Isolated AST or ALT', 'baseline', 'Regular and frequent checking of LFTs (e.g., every 1-2 days) until', 'elevations of these are improving or resolved.', '>8.0xULN and', 'Resume study drug/study regimen if', '-', '<20.0xULN, if normal', 'elevations downgrade to Grade 1 or', 'Consult hepatologist (unless investigator is hepatologist); obtain', 'baseline within 14 days and after', 'abdominal ultrasound, including Doppler assessment of liver perfusion;', 'at baseline)', 'completion of steroid taper.', 'and consider liver biopsy.', '-', 'Consider, as necessary, discussing with study physician.', 'Permanently discontinue study', '-', 'drug/study regimen if the elevations', 'If investigator suspects toxicity to be immune-mediated, promptly', '(Isolated AST or ALT', 'do not downgrade to Grade <1 or', 'initiate empiric IV methylprednisolone at 1 to 4 mg/kg/day or', '>12.5xULN and', 'baseline within 14 days', 'equivalent.', '<20.0xULN, if', '-', 'If no improvement within 3 to 5 days despite 1 to 4 mg/kg/day', 'Permanently discontinue study drug/study', 'elevated >ULN at', 'methylprednisolone IV or equivalent, obtain liver biopsy (if it has not', \"regimen for any case meeting Hy's law\", 'been done already) and promptly start treatment with', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 97 de 123']['baseline)', 'criteria, in the absence of any alternative', 'immunosuppressive therapy (mycophenolate mofetil). Discuss with', 'study physician if mycophenolate is not available. Infliximab should', 'cause.b', 'NOT be used.', 'Once the patient is improving, gradually taper steroids over >28 days', 'and consider prophylactic antibiotics, antifungals, and anti-PCP', 'treatment (refer to current NCCN guidelines for treatment of cancer-', 'related infections [Category 2B recommendation].', 'Grade 4', 'Permanently discontinue study drug/study', 'For Grade 4:', '(Isolated AST or ALT', 'regimen.', 'Same as above', '>20xULN, whether', '(except would recommend obtaining liver biopsy early)', 'normal or elevated at', 'baseline)', 'If transaminase rise is not isolated but (at any time) occurs in setting of either increasing total/direct bilirubin (1.5xULN, if normal at baseline; or 2xbaseline, if >ULN at baseline) or signs of', 'DILI/liver decompensation (e.g., fever, elevated INR):', '-', 'Manage dosing for Grade 1 transaminase rise as instructed for Grade 2 transaminase rise', '-', 'Manage dosing for Grade 2 transaminase rise as instructed for Grade 3 transaminase rise', '-', 'Grade 3-4: Permanently discontinue study drug/study regimen', 'Nephritis or renal dysfunction', 'Any Grade', 'General Guidance', 'For Any Grade:', '-', '(elevated serum creatinine)', 'Consult with nephrologist.', '-', 'Monitor for signs and symptoms that may be related to changes in renal', 'function (e.g., routine urinalysis, elevated serum BUN and creatinine,', 'decreased creatinine clearance, electrolyte imbalance, decrease in urine', 'output, or proteinuria).', '-', 'Patients should be thoroughly evaluated to rule out any alternative', 'etiology (e.g., disease progression or infections).', '-', 'Steroids should be considered in the absence of clear alternative', 'etiology even for low-grade events (Grade 2), in order to prevent', 'potential progression to higher grade event.', 'Grade 1', 'No dose modifications.', 'For Grade 1:', '-', '(Serum creatinine > 1', 'Monitor serum creatinine weekly and any accompanying symptoms.', 'If creatinine returns to baseline, resume its regular monitoring', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 98 de 123']\n\n###\n\n", "completion": "END"}